Press release
Compugen Announces Leadership Transitions Effective September 2025
Anat Cohen-Dayag, Ph.D., appointed as Executive Chair of the Board of DirectorsEran Ophir, Ph.D., appointed as President and Chief Executive Officer and will
About this update from Compugen Ltd.
[{"type":"text","content":"Anat Cohen-Dayag, Ph.D., appointed as Executive Chair of the Board of DirectorsEran Ophir, Ph.D., appointed as President and Chief Executive Officer and will join the Board of DirectorsPaul Sekhri to step down as Chair of the Board of DirectorsHOLON, Israel, May 13, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced key leadership transitions to take effect in September 2025 following the Annual General Meeting. Anat Cohen-Dayag, Ph.D., currently President and Chief Executive Officer will assume the newly created role of Executive Chair of the Board of Directors, subject to shareholder approval. Eran Ophir, Ph.D., currently Chief Scientific Officer, has been appointed President and Chief Executive Officer and will join the Board of Directors, subject to shareholder approval. Paul Sekhri will step down as Chair of the Board of Directors.\n\nDr. Cohen-Dayag has led Compugen as President and CEO since 2010. Under her leadership, the Company transformed into a therapeutic discovery and development company advancing a differentiated immuno-oncology pipeline based on Unigen™, Compugen's proprietary AI/ML-driven computational discovery platform. The Company's clinical-stage assets include the wholly owned COM701 and COM902, and milestone and royalty-bearing rilvegostomig (partnered with AstraZeneca, an Fc-reduced PD-1/TIGIT bispecific, the TIGIT component of which is derived from COM902), and GS-0321 (previously COM503, partnered with Gilead).\nIn her new role as Executive Chair, Dr. Cohen-Dayag will focus on Compugen's corporate strategy, strategic collaborations, and be involved in investor relations.\nPaul Sekhri, outgoing Chair of the Board, stated, \"As I step down as Chair of the Board after 8 years in the position, I do so with full confidence that Compugen is in exceptional hands. The leadership of Anat as Executive Chair and Eran as President and CEO ensures a strong foundation for the Company's next phase of growth.\"\nDr. Cohen-Dayag commented, \"I am proud of all we have accomplished: advancing an innovative clinical immunotherapy pipeline, establishing strategic collaborations, and building a robust foundation with a talented management team and a cash runway into 2027. This is the right moment to pass...